Cargando…
Case Management of COVID-19 (Secondary Version)
Case management of COVID-19 is critically important to save lives and reduce the fear and anxiety evoked by this disease in communities. However, most healthcare systems have been overwhelmed in many parts of the world. It is also essential to screen patients to be able to identify those who are lik...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Japan Medical Association
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8355701/ https://www.ncbi.nlm.nih.gov/pubmed/34414312 http://dx.doi.org/10.31662/jmaj.2021-0036 |
_version_ | 1783736813193527296 |
---|---|
author | Kato, Yasuyuki |
author_facet | Kato, Yasuyuki |
author_sort | Kato, Yasuyuki |
collection | PubMed |
description | Case management of COVID-19 is critically important to save lives and reduce the fear and anxiety evoked by this disease in communities. However, most healthcare systems have been overwhelmed in many parts of the world. It is also essential to screen patients to be able to identify those who are likely to suffer from severe disease, to ensure more effective use of medical resources. Disease severity can be determined based on simple vital signs; some laboratory markers are useful adjuncts. Treatment for COVID-19 is largely supportive although a number of repurposed drugs have been evaluated for its efficacy in clinical trials. For example, dexamethasone has now been considered as a standard therapy for severe cases, while remdesivir and tocilizumab are promising agents in selected patient groups. |
format | Online Article Text |
id | pubmed-8355701 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Japan Medical Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-83557012021-08-18 Case Management of COVID-19 (Secondary Version) Kato, Yasuyuki JMA J Review Article: COVID-19 Case management of COVID-19 is critically important to save lives and reduce the fear and anxiety evoked by this disease in communities. However, most healthcare systems have been overwhelmed in many parts of the world. It is also essential to screen patients to be able to identify those who are likely to suffer from severe disease, to ensure more effective use of medical resources. Disease severity can be determined based on simple vital signs; some laboratory markers are useful adjuncts. Treatment for COVID-19 is largely supportive although a number of repurposed drugs have been evaluated for its efficacy in clinical trials. For example, dexamethasone has now been considered as a standard therapy for severe cases, while remdesivir and tocilizumab are promising agents in selected patient groups. Japan Medical Association 2021-07-09 2021-07-15 /pmc/articles/PMC8355701/ /pubmed/34414312 http://dx.doi.org/10.31662/jmaj.2021-0036 Text en Copyright © Japan Medical Association https://creativecommons.org/licenses/by/4.0/JMA Journal is an Open Access journal distributed under the Creative Commons Attribution 4.0 International License. To view the details of this license, please visit (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ). |
spellingShingle | Review Article: COVID-19 Kato, Yasuyuki Case Management of COVID-19 (Secondary Version) |
title | Case Management of COVID-19 (Secondary Version) |
title_full | Case Management of COVID-19 (Secondary Version) |
title_fullStr | Case Management of COVID-19 (Secondary Version) |
title_full_unstemmed | Case Management of COVID-19 (Secondary Version) |
title_short | Case Management of COVID-19 (Secondary Version) |
title_sort | case management of covid-19 (secondary version) |
topic | Review Article: COVID-19 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8355701/ https://www.ncbi.nlm.nih.gov/pubmed/34414312 http://dx.doi.org/10.31662/jmaj.2021-0036 |
work_keys_str_mv | AT katoyasuyuki casemanagementofcovid19secondaryversion |